Jan. 19, 2024—Cepheid announced it has received FDA clearance with a CLIA waiver for the Xpert Xpress MVP, a multiplex vaginal panel that can now be performed in near-patient settings. The test is intended to aid in the diagnosis of bacterial vaginosis, vulvovaginal candidiasis, and trichomoniasis from a single specimen. It runs on Cepheid’s GeneXpert Xpress instruments and provides results within an hour.